Hemostasis

World Thrombosis Day Campaign Activates Global Awareness Efforts on Evidence-Based Prevention of Blood Clots for Ninth Consecutive Year

Retrieved on: 
Thursday, October 13, 2022

CHAPEL HILL, N.C., Oct. 13, 2022 /PRNewswire/ -- Today is World Thrombosis Day, a global awareness campaign led by the International Society on Thrombosis and Haemostasis (ISTH), recognized annually on October 13 to bring awareness to conditions caused by thrombosis, commonly known as a blood clot(s), that are responsible for one in four deaths worldwide. 

Key Points: 
  • "Blood clots are often overlooked because their symptoms can resemble those of many other conditions," shared Professor Beverley Hunt, MD, OBE, Chair of the World Thrombosis Day Steering Committee.
  • World Thrombosis Day shares these key tips to help prevent blood clots:
    Know the signs and symptoms of a blood clot.
  • "We encourage everyone across the globe to get involved in World Thrombosis Day to increase public awareness and education about blood clots," said Professor Flora Peyvandi, MD, ISTH President.
  • To learn more about blood clots and to participate in World Thrombosis Day, visit www.worldthrombosisday.org and follow #WTDay22 on social media.

Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall

Retrieved on: 
Tuesday, October 11, 2022

AC5 is a proprietary self-assembling, synthetic wound care product that provides multi-modal support to clinicians and has utility across all phases of wound healing.

Key Points: 
  • AC5 is a proprietary self-assembling, synthetic wound care product that provides multi-modal support to clinicians and has utility across all phases of wound healing.
  • The following clinical cases, which examine the use of AC5 in patients with acute, chronic, and challenging wounds, will be presented.
  • Arch has received regulatory clearance to market AC5 Advanced Wound System in the United States and AC5 Topical Hemostat in Europe.
  • 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

ZEISS Receives FDA Clearance for MTLawton - A New Generation of Bipolar Forceps for Electrosurgery

Retrieved on: 
Monday, October 10, 2022

JENA, Germany, Oct. 10, 2022 /PRNewswire/ -- ZEISS Medical Technology announced that it has received 510(k) clearance from the FDA for MTLawton™. These new disposable bipolar forceps are made from a special copper-base alloy and potentially reduce tissue adhesion and subsequent charring during dissection of tissue. Thanks to the extended shaft, the forceps also reduce visual restrictions in the surgical field and help surgeons to be efficient during electrosurgical procedures.

Key Points: 
  • JENA, Germany, Oct. 10, 2022 /PRNewswire/ --ZEISS Medical Technology announced that it has received 510(k) clearance from the FDA for MTLawton.
  • The development of the new bipolar forceps from ZEISS is based on close collaboration with Michael T. Lawton, one of the world's leading neurosurgeons.
  • "The MTLawton Disposable Bipolar Forceps are a real advance in electrosurgery over aluminum forceps.
  • MTLawton from ZEISS takes non-stick technology to a whole new level by introducing our bipolar forceps made of a special copper-base alloy.

Endpoint Health Unveils Precision Immunology Program to Address Tissue Factor-Mediated Inflammation in Autoimmune Diseases

Retrieved on: 
Tuesday, October 4, 2022

Endpoint Health, Inc., a Precision-FirstTM therapeutics company, today unveiled its newest precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling.

Key Points: 
  • Endpoint Health, Inc., a Precision-FirstTM therapeutics company, today unveiled its newest precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling.
  • Tissue factor has been a historically under-exploited central biological target and is a fundamental mediator of innate immune activity and coagulation.
  • This newly unveiled precision immunology program was made possible by Endpoint Healths recent acquisition of Iconic Therapeutics, a preclinical-stage biotech company developing selective therapies including ICON4 (now EP004) to address TF-mediated signaling.
  • Endpoint Health is a Precision-FirstTM therapeutics company dedicated to addressing unmet needs in immune-mediated chronic and acute diseases.

Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions

Retrieved on: 
Thursday, September 29, 2022

Selectas Chief Scientific Officer, Kei Kishimoto, Ph.D., was a key contributor to this foundational work during his time in Dr. Springers lab.

Key Points: 
  • Selectas Chief Scientific Officer, Kei Kishimoto, Ph.D., was a key contributor to this foundational work during his time in Dr. Springers lab.
  • Tims contributions to the field of immunology are truly monumental, said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta Biosciences.
  • Selecta Biosciences Inc.(NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.
  • The Company specifically disclaims any intention to update any forward-looking statements included in this press release except as required by law.

Global Hemostasis Diagnostics Market Report 2022: Rising Incidences of Blood Clotting Disorders Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, September 26, 2022

The "Hemostasis Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hemostasis Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The global hemostasis diagnostics market is expected to grow at a CAGR of 8.1% over the forecast period.
  • Rising incidences of blood clotting diagnosis for patients particularly who are more prone to lose excess blood from body during surgeries is the major factors contributing to the growth of the market.
  • However, lack of awareness regarding hemostasis disorders in underdeveloped regions and stringent government regulation may restrict the market.

Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program

Retrieved on: 
Friday, September 23, 2022

FRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (Arch or the Company), a marketer and developer of novel self-assembling wound care and biosurgical products, today confirmed the first shipments of AC5 Advanced Wound System (AC5) under the Companys new reimbursement support program (the Program).

Key Points: 
  • FRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (Arch or the Company), a marketer and developer of novel self-assembling wound care and biosurgical products, today confirmed the first shipments of AC5 Advanced Wound System (AC5) under the Companys new reimbursement support program (the Program).
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.
  • This is an exciting time for Arch and the launch of the reimbursement support program represents a huge step forward.
  • Arch has received regulatory clearance to market AC5 Advanced Wound System in the United States and AC5 Topical Hemostat in Europe.

Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)

Retrieved on: 
Tuesday, September 20, 2022

FRAMINGHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (Arch or the Company), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that AC5 Advanced Wound System (AC5) was selected for the Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care session at the 2022 Symposium on Advanced Wound Care (SAWC).

Key Points: 
  • FRAMINGHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (Arch or the Company), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that AC5 Advanced Wound System (AC5) was selected for the Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care session at the 2022 Symposium on Advanced Wound Care (SAWC).
  • AC5 is a novel self-assembling wound care product and is the first to provide clinicians with multi-modal support and utility across all phases of wound healing.
  • The Symposium on Advanced Wound Care (SAWC) is the largest gathering of multidisciplinary wound care clinicians in the United States.
  • Arch has received regulatory clearance to market AC5 Advanced Wound System in the United States and AC5 Topical Hemostat in Europe.

Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange

Retrieved on: 
Friday, September 16, 2022

The move to a national exchange should improve capital market access for existing and prospective new investors, as well as enhance the Companys ability and plan to raise the necessary capital to drive growth.

Key Points: 
  • The move to a national exchange should improve capital market access for existing and prospective new investors, as well as enhance the Companys ability and plan to raise the necessary capital to drive growth.
  • The listing requirements necessary to consummate the Uplisting include the following:
    Concurrent Equity Financing to Strengthen the Balance Sheet.
  • Arch Therapeutics, Inc. is a biotechnology company with a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma, and interventional care.
  • Arch has received regulatory clearance to market AC5 Advanced Wound System in the United States and AC5 Topical Hemostat in Europe.

New Medcura SVP Positions LifeGel™ Surgical Hemostat for Market Leadership

Retrieved on: 
Thursday, September 15, 2022

RIVERDALE, Md., Sept. 15, 2022 /PRNewswire/ -- Medcura Inc. welcomes Steve Ford, its new Senior Vice President of Marketing and Business Development, whose two-plus decades of experience leading and contributing to over 75 product development teams, and launching more than 100 medical devices globally, helps position the commercial-stage life science and medical device company for broad market adoption and rapid platform expansion.

Key Points: 
  • Those products include surgical gels, foams, powders and putties such as LifeGel Absorbable Surgical Hemostat, LifeFoam recently cited in research as having "significant potential" to save lives in military combat settings and at-home consumer products such as the antibacterial wound gel Rapid-Seal available at major retailers.
  • I'm thrilled to join the Medcura team and bring their life-changing and saving products to the global market."
  • Unlike the expensive-to-manufacture enzyme thrombin, commonly used in blood clotting products, Medcura products' active components are both low-cost and sustainable.
  • Medcura is a commercial-stage medical device company developing versatile hemostatic products for surgical, medical, and consumer applications.